Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib

Molecular Cancer Therapeutics

Volumn 9, Issue 11, 2010, Pages 3083-3089

  Gaillard, Jean Baptiste ^a,b   Arnould, Cécile ^a   Bravo, Sophie ^a   Donadio, Daniel ^c   Exbrayat, Carole ^c   Jourdan, Eric ^a   Reboul, Dorothée ^a,b   Chiesa, Jean ^a,b   Lavabre Bertrand, Thierry ^a,b  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c Clinique du Parc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ALTERNATIVE RNA SPLICING; AMPLICON; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENETIC PROCEDURES; GENETIC SCREENING; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPLICING DEFECT;

ANTINEOPLASTIC AGENTS; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; EXONS; FUSION PROTEINS, BCR-ABL; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC TESTING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NUCLEIC ACID DENATURATION; PIPERAZINES; PROTEIN ISOFORMS; PYRIMIDINES; TEMPERATURE;

EID: 78649637757     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0595     Document Type: Article

References (34)

1. Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol 2007;44:S4-14.
2. Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon- α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002;99:1527-35.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
4. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
5. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-42.
6. O'Dwyer ME, Druker BJ. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol 2000:1207-211.
7. Michallet M, Tulliez M, Corm S, et al. Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study. Curr Med Res Opin 2010;26:307-17.
8. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-29.
9. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374-9.
10. Jones D, Kamel-Reid S, Bahler D, et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn 2009;11:4-11.
11. Gruber FX, Hjorth-Hansen H, Mikkola I, Stenke L, Johansen T. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Leukemia 2006;20:2057-60.
12. Laudadio J, Deininger MWN, Mauro MJ, Druker BJ, Press RD. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn 2008;10:177-80.
13. Hayette S, Chabane K, Tchirkov A, Berger MG, Nicolini FE, Tournilhac O. Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia. Haematologica 2009;94:1324-6.
14. Curvo RPM, Zalcberg IR, Scholl V, Pires V, Moellmann-Coelho A, Moreira MAM. A recurrent splicing variant without c-ABL exon 7 in imatinib-resistant patients. Leuk Res 2008;32:508-10.
15. Cho EH, Kang SK, Kim SY. Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on "A recurrent splicing variant without c-ABL exon 7 in imatinib-resistant patients" by Curvo et al. [Leuk. Res]. Leuk Res 2009;33:505-6.
16. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009;27:6041-51.
17. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-5.
18. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L.Molecularmechanisms of resistance to imatinib in Philadelphia- chromosome-positive leukaemias. Lancet Oncol 2003;4:75-85.
19. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
20. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767-73.
21. Poláková KM, Lopotová T, Klamová H, Moravcová J. High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain. Leuk Res 2008;32:1236-43.
22. Kang H, Hwang J, Kim S, Goh H, Kim M, Kim D. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica 2006;91:659-62.
23. Tazi J, Bakkour N, Stamm S. Alternative splicing and disease. Biochim Biophys Acta 2009;1792:14-26.
24. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009;10:741-54.
25. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1986;47:277-84.
26. Dagan T, Sorek R, Sharon E, Ast G, Graur D. AluGene: a database of Alu elements incorporated within protein-coding genes. Nucleic Acids Res 2004;32:D489-92.
27. Fairbrother WG, Yeh R, Sharp PA, Burge CB. Predictive identification of exonic splicing enhancers in human genes. Science 2002;297:1007-13.
28. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004;64:7647-54.
29. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 2007;39:1432-49.
30. Santamaria I, Pitiot AS, Balbin M. ABL alternative splicing is quite frequent in normal population - letter. Mol Cancer Ther 2010;9:772, author reply 772.
31. Lee T, Ma W, Zhang X, et al. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther 2008;7:3834-41.
32. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:33-44. (Pubitemid 38089839)
33. Pan Q, Saltzman AL, Kim YK, et al. Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense-mediated mRNA decay to control gene expression. Genes Dev 2006;20:153-8.
34. Sherbenou DW, Hantschel O, Turaga L, et al. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia 2008;22:1184-90.